Onkologicky Ustav Sv Alzbety s.r.o. — Clinical Trial Site

10 Registered trials

4 Currently recruiting

Organisation

Onkologicky Ustav Sv Alzbety s.r.o.

Location

Bratislava, Slovakia

Identifier

ORG-100041589

Address

Heydukova 10, Stare Mesto, 811 08, Slovakia

Departments

#2401: Interná klinika VŠZaSP a OÚSA
Department of Oncology
I. onkologická klinika LF UK a OÚSA
I. Onkologická klinika LFUK a OÚSA
Interna klinika VSZaSP a OUSA
Interná onkologická klinika
onkologická klinika
Onkologický ústav
Outpatient care of clinical oncology

Clinical trials at this site (10)

Search interface

Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting

2022-500544-38-00 Advanced Breast Cancer 5 2023-06-05
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Breast Neoplasms 5 2023-04-18
A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K in… Recruiting

2022-501152-28-00 Breast Cancer 4 2022-12-21
A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advan… Recruiting

2025-520566-22-00 Hormone Receptor-Positive, HER2-Negative Advanced/Metas 5 2025-11-10
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended

2024-512925-95-00 Advanced/Metastatic Breast Cancer 5 2025-05-16
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable… Ended

2023-504195-14-00 PD-L1-negative metastatic triple-negative breast cancer 5 2022-08-31
A Phase 1/2a study of PF-07220060 in Participants with Advanced Solid Tumors Ended

2024-512120-11-00 Part 2A, 2B, 2C & 2E HR-positive /HER2-negative breast 7 2022-08-31
A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cance… Ended

2023-509133-39-00 Hormone receptor positive, HER2-negative advanced breas 5 2021-11-29
A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER… Ended

2023-503995-26-00 Estrogen Receptor-Positive, HER2-Negative Advanced Brea 5 2021-05-11
A study of patients with colorectal cancer that have a genetic abnormality in the BRAF gene taking encorafenib plus cetuximab with or withou… Ended

2023-509405-77-00 Colorectal cancer (BRAF V600E-mutant mCRC) 5 2021-02-16